XTL Biopharmaceuticals (XTLB)
(Delayed Data from NSDQ)
$2.61 USD
0.00 (0.00%)
Updated May 28, 2024 12:51 PM ET
After-Market: $2.55 -0.06 (-2.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for XTL Biopharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -1 | -1 | -1 | -1 | -1 |
Non-Operating Income | -1 | 0 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -2 | -1 | 0 | -1 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -2 | -1 | 0 | -1 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -2 | -1 | 0 | -1 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -1 | -1 | -1 | -1 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -1 | -1 | -1 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.45 | 544.91 | 6.16 | 5.14 | 5.14 |
Diluted EPS Before Non-Recurring Items | -0.33 | 0.00 | 0.07 | -0.15 | -0.30 |
Diluted Net EPS (GAAP) | -0.30 | -0.20 | 0.10 | -0.20 | -0.30 |
Fiscal Year end for XTL Biopharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | NA | NA | NA | 0.00 |
Gross Profit | 0.00 | NA | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.18 | 0.00 | 0.00 | 0.00 | 0.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.18 | 0.00 | 0.00 | 0.00 | -0.25 |
Non-Operating Income | 0.68 | NA | NA | NA | -0.64 |
Interest Expense | 0.02 | NA | NA | NA | 0.03 |
Pretax Income | 0.49 | NA | NA | NA | -0.92 |
Income Taxes | 0.00 | NA | NA | NA | 0.00 |
Minority Interest | 0.00 | NA | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | NA | NA | 0.00 |
Other Income/Charges | 0.00 | NA | NA | NA | 0.00 |
Income From Cont. Operations | 0.49 | NA | -0.22 | -0.36 | -0.92 |
Extras & Discontinued Operations | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.49 | NA | -0.22 | -0.36 | -0.92 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 5.45 | NA | 5.45 | 5.45 | 5.45 |
Diluted EPS Before Non-Recurring Items | 0.10 | NA | -0.04 | -0.07 | -0.17 |
Diluted Net EPS (GAAP) | 0.10 | NA | -0.04 | -0.07 | -0.17 |